<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>Gestational Trophoblastic Diseases (GTDs)</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <!-- <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li> -->
    </ul>
  </nav>
  
  <main class="page-container">
    <!-- <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div> -->

    <h1>Gestational Trophoblastic Diseases (GTDs)</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Origin/biology</a></li>
            <li><a href="#header-3">Classification of GTDs</a></li>
            <ul>
                <li><a href="#heading-3-1">	Benign (Hydatidiform mole)</a></li>
                <li><a href="#heading-3-2">	Malignant GTDs</a></li>
            </ul>
            <li><a href="#header-4">Conclusion</a></li>

         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <p>Gestational trophoblastic disease (GTD) is a spectrum of tumors that develop from an aberrant fertilization event and hence arise from fetal tissue within the maternal host, this makes them unique.</p>
            <p>They arise from over-production of chorionic tissue (which usually should develop into the placenta)</p>
            <p>GTD represents a spectrum of premalignant and malignant diseases</p>
            <p>They have varying propensities for local invasion and metastasis. </p>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Origin/Biology</a>
          </h2>
        </header>
        <div class='body'>
            <p>The trophoblast is extraembryonic but fetal in origin.</p>
            <p>The trophoblastic cells are the epithelial component of the placenta and are divided into three cytologically and functionally distinct populations. </p>
            <ol>
                <li>Cytotrophoblastic(CT) cells </li>
                <li>Syncytiotrophoblastic(ST) cells </li>
                <li>Intermediate trophoblastic (IT) cells</li>
            </ol>

            <h4><span class="special-text-4b">Cytotrophoblast </span></h4>
            <ul>
                <li>The cytotrophoblast is a stem cell with high mitotic activity but without hormonal synthesis</li>
            </ul>
            <h4><span class="special-text-4b">Intermediate trophoblast</span></h4>
            <ul>
                <li>The intermediate trophoblast has features of the other two components and is responsible for endometrial invasion and implantation</li>
            </ul>
            <h4><span class="special-text-4b">Syncytiotrophoblast</span></h4>
            <ul>
                <li>The syncytiotrophoblast constitutes the villous trophoblast. It has low mitotic activity. The syncytiotrophoblast is responsible for the synthesis of the beta-hCG.</li>
            </ul>


            <p>Trophoblastic cells express a number of proteins.</p>
            <ul>
                <li>B-hCG (human Chorionic Gonadotrophin)</li>
                <li>hPL (human Placental lactogen)</li>
                <li>Placental alkaline phosphatase (PLAP)</li>
                <li>Inhibin-a</li>
            </ul>
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification of GTDs</a>
          </h2>
        </header>
        <div class='body'>
            <ol>
                <li>Benign Forms (90%)</li>
                <ul>
                    <li>Complete hydatidiform mole (CHM)</li>
                    <li>Partial hydatidiform mole (PHM)</li>
                </ul>
                <li>Malignant Forms (10%)</li>
                <ul>
                    <li>Invasive mole</li>
                    <li>Choriocarcinoma</li>
                    <li>Placental site trophoblastic tumor (PSTT)</li>
                    <li>Epithelioid trophoblastic tumor</li>
                </ul>
            </ol>

            <div class="tips-card">
                <p class="tips-card-subtitle">note</p>
                <h4 class="tips-card-title">
                  Points to note
                </h4>
                <p class="tips-card-content">
                  <ul>
                    <li>Complete molar pregnancies are generally diploid, and all chromosomes are of paternal origin.</li>
                    <li>Complete moles are being diagnosed earlier in pregnancy and less frequently present with the classic signs and symptoms.</li>
                    <li>Partial molar pregnancies are triploid, and the extra set of chromosomes is paternal</li>
                    <li>Although malignant gestational trophoblastic diseases most commonly follow a molar pregnancy, they can occur after any gestational event, including induced or spontaneous abortion, ectopic pregnancy, or term pregnancy.</li>
                  </ul>
                    
                </p>
              </div>

              <section id='heading-3-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-1'>Benign (Hydatidiform mole)</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>Can be complete or partial mole</p>

                    <section id='heading-3-1-1'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-1'>Epidermiology</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Hydatidiform mole is the most common form of gestational trophoblastic disease and is benign in nature.</p>
                            <p>2% of all miscarriages.</p>
                            <p>Its incidence varies worldwide. </p>
                            <ul>
                                <li>1 in 1500 deliveries in the United States</li>
                                <li>1 in 400 pregnancy in Nigeria</li>
                                <li>1 in 200 pregnancy in Indonesia</li>
                                <li>1 in 125 deliveries in Mexico and Taiwan </li>
                            </ul>
                
                        </div>
                    </section>

                    <section id='heading-3-1-2'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-2'>Risk Factors</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <ul>
                                <li>Race (blacks/Asians). In many Asian countries, the rates may be as high as 8â€“10 cases per 1,000 population.</li>
                                <li>Age <20yrs; >40yrs. The risk of development of H. mole in women older than 40 years is about five times more than that in younger women.</li>
                                <li>Parity- Nulliparity.</li>
                                <li>Low SES (Socioeconomic Status).</li>
                                <li>Deficiency of protein, folic acid and carotene.</li>
                                <li>Blood group- O highest; A least.</li>
                                <li>Previous history of molar pregnancy.</li>
                                <li>Partial mole is reported to be associated with the use of oral contraceptives, history of irregular menstruation and not with dietary factors</li>
                            </ul>
                
                        </div>
                    </section>

                    <section id='heading-3-1-3'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-3'>Clinical Presentation</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Abnormal vaginal bleeding (75%) +/- passage of vesicles</p>
                            <p>Initially, the symptoms may be suggestive of early pregnancy; however the uterus is often larger than the period of gestation. </p>
                            <p>Absent fetal movements and heart tones</p>
                            <p>Passage of grape-like tissue is strongly suggestive of the diagnosis of H. mole.</p>
                            <p>Excessive nausea and vomiting.</p>
                            <p>Symptoms suggestive of hyperthyroidism (tachycardia, restlessness, nervousness, heat intolerance, unexplained weight loss, diarrhea, tremors in hands, etc.)</p>
                            <p>Excessive nausea and vomiting in cases of H mole may be related to high serum levels of Î² hCG. Hyperemesis may commonly occur.</p>
                            <p> Commonly the nausea and vomiting may be severe enough to require hospitalization.</p>
                            <p>Early-onset pre-eclampsia</p>
                            <p>Anaemia</p>
                            <p>Thrombo-embolism</p>
                            <p>Large theca lutein cysts</p>
                            <p>Metastasis to the lungs (in cases of malignant moles) may result in symptoms like dyspnea, cough, hemoptysis, chest pain, etc.</p>
                
                            <figure>
                                <img src="/figures/gtd (1).png" alt="">
                                <figcaption> Clinical and Cytogenetic Comparison of Hydatidiform Moles</figcaption>
                               </figure>
                        </div>
                    </section>

                    <section id='heading-3-1-4'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-4'>Investigations</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Ultrasound Scan</p>
                            <ul>
                                <li>USS in the first trimester may not be reliable. The typical â€˜snowstormâ€™ appearance occurs mainly in the second trimester, showing a heterogenous mass with no fetal development.</li>
                                <figure>
                                    <img src="/figures/gtd (3).jpg" alt="">
                                    <figcaption> </figcaption>
                                   </figure>
                                <li>Large ovarian cysts, called theca-lutein cysts can also be seen. They are often bilateral</li>
                            </ul>
                            <p>Histology</p>
                            <ul>
                                <li>Definitive diagnosis is made by histological examination of the product of conception.</li>
                                <li>Different forms of GTD have distinctive morphological features, depending on which tissues they are derived from.</li>
                            </ul>
                            <p>Serum HCG</p>
                            <p>Complete blood picture</p>
                            <p>Renal and Liver function tests</p>
                            <p>Chest X-ray</p>
                            <p>Thyroid function test</p>
                
                        </div>
                    </section>

                    <section id='heading-3-1-5'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-5'>Treatment</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <h4><span class="special-text-4">Supportive (Medical)</span></h4>
                            <p>Stabilize patient.</p>
                            <ul>
                                <li>Transfuse for anemia.</li>
                                <li>Correct any coagulopathy.</li>
                                <li>Treat hypertention.</li>
                            </ul>
                            <p>Watch and prepare for treatment of thyroid storm.</p>
                
                            <h4><span class="special-text-4">Definitive (Surgical)</span></h4>
                            <ul>
                                <li>Suction curettage with high pressure pump is the method of choice.</li>
                                <li>Intravenous oxytocin should be started at the commencement of Suction curettage.</li>
                                <li>All Rh-negative patients should receive Anti-D immune globulin.</li>
                                <li>Send Products evacuated for Histology.</li>
                            </ul>

                            <div class="tips-card">
                                <p class="tips-card-subtitle">note</p>
                                <h4 class="tips-card-title">
                                  Other treatment modalities?
                                </h4>
                                <p class="tips-card-content">
                                  <ul>
                                    <li>Hysterectomy remains an option for good surgical candidates not desirous of future pregnancy and for older women; this procedure may reduce the risk of subsequent malignancy</li>
                                    <li>Hysterotomy is not a method of choice in typical cases.</li>
                                    <li>Medical induction is not an acceptable method.</li>
                                  </ul>
                                    
                                </p>
                              </div>
        
                        </div>
                    </section>

                    <section id='heading-3-1-6'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-6'>Post Molar Pregnancy Surveillance</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <h4><span class="special-text-4b">1. Serial Î²â€“hCG.</span></h4>
                            <ul>
                                <li>Beginning within 48 hours after evacuation and then at weekly intervals until serum -hCG declines to nondetectable levels on three successive assays.</li>
                                <li>(In benign disease, human chorionic gonadotropin concentrations spontaneously return to normal by eight weeks following evacuation of molar pregnancy)</li>
                                <li>Monthly for at least 1 year.</li>
                            </ul>

                            <h4><span class="special-text-4b">2. Gynaecologic examinations. </span></h4>
                            <ul>
                                <li>Uterine size and presence of adnexal masses (theca lutein cysts) and a careful search of the vulva, vagina, urethra, and cervix should be made for evidence of genital tract metastases.</li>
                                <li>Commence one week after evacuation.</li>
                                <li>Repeated at 4-week intervals for one year.</li>
                            </ul>

                            <h4><span class="special-text-4b">3. Chest radiography. </span></h4>
                            <ul>
                                <li>Pre - evacuation Chest X-ray.</li>
                                <li>Then at 3-month intervals for one year</li>
                            </ul>

                            <h4><span class="special-text-4b">4. Contraception for one year</span></h4>
                            <p>(Aim of 1, 2, 3, above is to determine if there is need for Chemotherapy)</p>

                
                        </div>
                    </section>

                    <section id='heading-3-1-7'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-7'>Prognosis</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>Excellent following evacuation.</p>
                            <p>However 10â€“15% of patients develop malignant form of the disease.</p>
                
                        </div>
                    </section>

                    <section id='heading-3-1-8'>
                        <header>
                          <h4>
                
                            <a aria-hidden href='#heading-3-1-8'>Indications for Chemotherapy</a>
                          </h4>
                        </header>
                        <div class='body'>
                            <p>When the plateau of HCG lasts for four measurements over a period of 3 weeks or longer (day1, 7, 14, 21)</p>
                            <p>Serum level of hCG >20,000 IU/l more than 4 weeks after evacuation </p>
                            <p>Raised hCG level six months after evacuation</p>
                            <p>When there is a rise of hCG of three weekly consecutive measurements or longer over a period of 2 weeks or more (days 1, 7, 14)</p>
                            <p>Histological evidence of Choriocarcinoma</p>
                            <p>The presence of metastases in brain, liver, gastrointestinal tract, lungs, vulvar or vaginal walls.</p>
                
                            <figure>
                                <img src="/figures/gtd (2).jpeg" alt="">
                                <figcaption> </figcaption>
                               </figure>
                        </div>
                    </section>
                </div>
              </section>

              <section id='heading-3-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-3-2'>Malignant GTDs</a>
                  </h3>
                </header>
                <div class='body'>
                   <ul>
                    <li>Invasive mole</li>
                    <li>Choriocarcinoma</li>
                    <li>Placenta site trophoblastic tumor</li>
                   </ul>

                   <h4><span class="special-text-4">Invasive Mole</span></h4>
                   <ul>
                    <li>10 - 15% of patients who have undergone evacuation of a molar pregnancy.</li>
                    <li>Mole that penetrates or even perforates the uterine wall with invasion of the myometrium by Chorionic villi, accompanied by proliferation of both cytotrophoblast and syncytiotrophoblast.</li>
                    <li>Embolize to distant sites, such as lungs and brain, but do not grow in these organs as true metastases.</li>
                   </ul>
                   <h4><span class="special-text-4">Choriocarcinoma</span></h4>
                   <ul>
                    <li>2â€“5% of all cases of gestational trophoblastic neoplasia.</li>
                    <li>Derived from a previously normal or abnormal pregnancy </li>
                    <li>Malignant tumor derived from normal or abnormal placental tissue</li>
                    <li>Choriocarcinoma is a pure epithelial tumor composed of syncytiotrophoblastic and cytotrophoblastic cells.</li>
                    <li>Histologic evaluation of the tumor discloses sheets or foci of trophoblasts on a background of hemorrhage and necrosis, but no villi</li>
                   </ul>
                   <h4><span class="special-text-4"> Placenta Site Trophoblastic Tumor</span></h4>
                   <ul>
                    <li>PSTT is a rare variant of gestational trophoblastic tumor.</li>
                    <li>Compose less than 2% of gestational trophoblastic neoplasms - 75% of cases follow normal pregnancy,   5% of cases have preceding molar pregnancy.</li>
                    <li>Neoplastic proliferation of extravillous trophoblastic (intermediate trophoblast).</li>
                    <li>Syncytiotrophoblastic cells are generally absent from this tumor, minimal amounts of hCG are released in relation to the tumor burden. However, human placental lactogen is secreted.</li>
                   </ul>

                   <section id='heading-3-2-2'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-2'>Pathology</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Invasive mole</p>
                        <ul>
                            <li> Villi penetrate deeply: Myometrium, blood vessels</li>
                        </ul>
                        <p>Choriocarcinoma</p>
                        <ul>
                            <li>Tumor mass is dark-red, hemorrhagic, and nodular</li>
                        </ul>
                        <p>Placenta site trophoblastic tumour</p>
                        <ul>
                            <li>Deep uterine penetration, myometrial mass may be well localized or ill defined. Hemorrhage is not as conspicuous as in invasive mole or as in choriocarcinoma. </li>
                        </ul>
            
                    </div>
                   </section>

                   <section id='heading-3-2-3'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-3'>Diagnosis </a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Findings at post evacuation surveillance, OR</p>
                        <p>Presenting symptoms & signs of metastases - </p>
                        <ul>
                            <li>Sub-urethral nodule in the vagina</li>
                            <li>Hemoptysis    </li>
                            <li>Abdominal pain/tenderness </li>
                            <li>Hematuria</li>
                            <li>Seizures</li>
                            <li>Coma </li>
                        </ul>
            
                    </div>
                   </section>

                   <section id='heading-3-2-4'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-4'>Investigations</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Full blood count.</p>
                        <p>Renal and liver function tests.</p>
                        <p>Serum HCG.</p>
                        <p>Chest X-ray.</p>
                        <p>Ultrasound of pelvis and liver.</p>
                        <p>Brain MRI or CT Scanning</p>
                        <p>CT or MRI of other parts of body as indicated</p>
            
                    </div>
                   </section>

                   <section id='heading-3-2-5'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-5'>FIGO Anatomic Staging of GTN</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p>Stage 1: Disease confined to the uterus</p>
                        <p>Stage 2: GTT extends outside the uterus but is limited to genital structures (vagina, broad ligament, adnexa)</p>
                        <p>Stage 3: GTT extends to the lungs with or without genital tract involvement.</p>
                        <p>Stage 4: All other metastatic sites </p>
                        <p>The goal of the revised FIGO staging is to improve the assessment and clinical management of patients and to unify staging to allow for international comparisons in treatment success.</p>
            
                    </div>
                   </section>

                   <section id='heading-3-2-6'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-6'>Classification of Gestational Trophoblastic Diseases for Treatment and Prognosis.</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <ul>
                            <li>Non metastatic disease (stage I).</li>
                            <li>Low-risk metastatic - stages II and III (score < 7).</li>
                            <li>High-risk metastatic - stage IV (score â‰¥ 7)</li>
                        </ul>
                        <p> Risk factor score based on the WHO prognostic scoring system.</p>
                        
                        <figure>
                            <img src="/figures/gtd (4).png" alt="">
                            <figcaption> </figcaption>
                           </figure>
                           
                    </div>
                   </section>

                   <section id='heading-3-2-7'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-7'>Treatment</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <h4><span class="special-text-4">Low-risk metastatic disease</span></h4>
                           <ul>
                            <li>Single-agent Chemotherapy with methotrexate or Actinomycin D.</li>
                           </ul>
                           <h4><span class="special-text-4">High-risk metastatic disease</span></h4>
                           <p>Multiagent chemotherapy with or without adjuvant surgery or radiation therapy</p>
                           <p>High-risk metastatic disease multiagent Chemotherapy could be: </p>
                           <p>MAC - Methotrexate + Actinomycin D + Cyclophosphomide, OR</p>
                           <p>EMA-CO: Etoposide + Methotrexate + Actinomycin D â€“ Cyclophosphomide + Oncovin.</p>
                           <p>Adjuvant surgical procedures that may be needed in hemorrhage or refractory nodule not responsive to Chemotherapy in High risk disease include;</p>
                           <ul>
                            <li>Hysterectomy</li>
                            <li>Hepatic artery embolization</li>
                            <li>Craniotomy</li>
                            <li>Thoracotomy</li>
                           </ul>
            

                           <h4><span class="special-text-4">Treatment of PSTT </span></h4>
                           <ul>
                            <li>It is generally resistant to chemotherapy </li>
                            <li>Hysterectomy is the recommended route of treatment</li>
                            <li>Partial uterine resection involving the tumor is possible if the patient desires future fertility. </li>
                            <li>Chemotherapy is indicated in cases of metastatic disease.</li>
                           </ul>

                           <h4><span class="special-text-4">Follow-up after treatment for GTT.</span></h4>
                           <ul>
                            <li>Serum quantitative hCG levels should be obtained at 1-month intervals for 12 months.</li>
                            <li>Contraception should be maintained during treatment and for 1 year after completion of chemotherapy.</li>
                            <li>Pelvic ultrasound is recommended in the first trimester of a subsequent pregnancy to confirm a normal gestation.</li>
                            <li>Serum quantitative hCG level should be determined 6 weeks after any pregnancy.</li>
                           </ul>
                    </div>
                  </section>

                  <section id='heading-3-2-8'>
                    <header>
                      <h4>
            
                        <a aria-hidden href='#heading-3-2-8'>Prognosis</a>
                      </h4>
                    </header>
                    <div class='body'>
                        <h4><span class="special-text-4">Malignant non-metastatic disease.</span></h4>
                        <ul>
                            <li>Quite good, as almost all patients are cured.</li>
                            <li>90% of patients can preserve reproductive function.</li>
                        </ul>
                        <h4><span class="special-text-4">Metastatic disease</span></h4>
                        <ul>
                            <li>Best results are with EMACO chemotherapy and concurrent radiation as indicated.</li>
                            <li>About 75% - 85% of patients achieve remission with a 69% salvage rate.</li>
                        </ul>
            
                    </div>
                  </section>
                </div>
              </section>

        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Conclusion</a>
          </h2>
        </header>
        <div class='body'>
            <p>After achieving remission with chemotherapy, patients with gestational trophoblastic tumors can generally anticipate normal reproduction in the future.    </p>
        </div>
      </section>


      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <!-- <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p> -->
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia.[beta]</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
